Nurix Therapeutics (NASDAQ:NRIX) Shares Up 6.7%

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) was up 6.7% during mid-day trading on Monday . The stock traded as high as $16.81 and last traded at $16.81. Approximately 41,877 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 940,563 shares. The stock had previously closed at $15.75.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NRIX. Robert W. Baird increased their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the company an "outperform" rating in a research note on Thursday, April 11th. HC Wainwright reduced their target price on shares of Nurix Therapeutics from $35.00 to $19.00 and set a "buy" rating on the stock in a research report on Tuesday, February 20th. Needham & Company LLC reissued a "buy" rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, May 14th. Stifel Nicolaus restated a "buy" rating and set a $27.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, May 15th. Finally, Royal Bank of Canada increased their price target on Nurix Therapeutics from $22.00 to $23.00 and gave the company an "outperform" rating in a report on Thursday, April 11th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $21.88.

Nurix Therapeutics Stock Performance

The stock has a fifty day moving average price of $14.52 and a two-hundred day moving average price of $11.35. The firm has a market capitalization of $788.87 million, a P/E ratio of -6.12 and a beta of 2.10.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Wednesday, April 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.04. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. The business had revenue of $16.59 million during the quarter, compared to analyst estimates of $14.58 million. As a group, research analysts anticipate that Nurix Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Houte Hans Van sold 3,499 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total value of $44,892.17. Following the sale, the chief financial officer now owns 68,333 shares of the company's stock, valued at approximately $876,712.39. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,499 shares of the company's stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total value of $44,892.17. Following the completion of the transaction, the chief financial officer now owns 68,333 shares in the company, valued at approximately $876,712.39. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Christine Ring sold 1,596 shares of the business's stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $17.01, for a total value of $27,147.96. Following the transaction, the insider now owns 19,838 shares of the company's stock, valued at $337,444.38. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,489 shares of company stock valued at $112,904. 7.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nurix Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NRIX. ProShare Advisors LLC increased its stake in shares of Nurix Therapeutics by 9.1% during the first quarter. ProShare Advisors LLC now owns 11,978 shares of the company's stock valued at $176,000 after acquiring an additional 998 shares during the period. Public Employees Retirement System of Ohio raised its stake in shares of Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company's stock worth $747,000 after buying an additional 1,820 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Nurix Therapeutics by 14.8% in the third quarter. Principal Financial Group Inc. now owns 15,531 shares of the company's stock valued at $122,000 after buying an additional 2,002 shares during the period. Raymond James & Associates boosted its stake in Nurix Therapeutics by 3.1% during the fourth quarter. Raymond James & Associates now owns 101,006 shares of the company's stock valued at $1,042,000 after buying an additional 3,018 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Nurix Therapeutics by 67.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company's stock worth $138,000 after acquiring an additional 3,793 shares during the period.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.